Evelo Biosciences, Inc.

Equities

EVLO

US2997342025

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:08:38 2024-05-14 pm EDT			5-day change	1st Jan Change
0.0505 ^USD	+26.25%		+6.54%	-17.89%

May. 02	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 25	North American Morning Briefing : More Tech -2-	DJ

Evelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 14, 2023 at 07:30 am EDT

Evelo Biosciences, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 21.1 million compared to USD 30.56 million a year ago. Basic loss per share from continuing operations was USD 3.78 compared to USD 8.07 a year ago.
For the six months, net loss was USD 46.44 million compared to USD 60.42 million a year ago. Basic loss per share from continuing operations was USD 8.35 compared to USD 18.67 a year ago.

Latest news about Evelo Biosciences, Inc.

North American Morning Briefing : Stock Futures -2-	May. 02	DJ
North American Morning Briefing : More Tech -2-	Apr. 25	DJ
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
North American Morning Briefing : Investors -2-	Mar. 21	DJ
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index	Dec. 14	CI
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index	Dec. 11	CI
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Composite Index	Dec. 11	CI
Evelo Biosciences, Inc. Announces Marella Thorell Cease as Chief Financial Officer, Effective on December 1, 2023	Nov. 21	CI
Evelo Biosciences, Inc. Announces Simba Gill Ceases as Chief Executive Officer	Nov. 21	CI
Evelo Biosciences, Inc. Announces Executive Changes, Effective December 1, 2023	Nov. 21	CI
Evelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
TD Cowen Downgrades Evelo Biosciences to Market Perform From Outperform	23-10-18	MT
Sector Update: Health Care Stocks Retreat in Late Afternoon	23-10-17	MT
Sector Update: Health Care	23-10-17	MT
Top Midday Decliners	23-10-17	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	23-10-17	MT
Evelo Biosciences Says Phase 2 Trial of Psoriasis Treatment Did Not Meet Primary Endpoint; Shares Plunge Pre-Bell	23-10-17	MT
Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	23-10-17	CI
Medicenna Therapeutics Appoints Humphrey Gardner as Chief Medical Officer	23-10-10	MT
Evelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Morgan Stanley Adjusts Evelo Biosciences' Price Target to $10 From $2, Keeps Equalweight Rating	23-07-26	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	23-07-21	MT
Evelo Biosciences Signs Termination Agreement for Cambridge Office, Laboratory Space; Shares Up Premarket	23-07-21	MT

Chart Evelo Biosciences, Inc.

Duration

Period

More charts

Company Profile

Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. It has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are pharmaceutical preparations of single strains of microbes or their extracellular vesicles (EVs). Its product candidate, EDP1815, is an investigational oral biologic being developed for the treatment of inflammatory diseases. EDP1815 is in clinical development for both psoriasis, driven largely by Th17 inflammation, and atopic dermatitis, driven by TH2 inflammation. EDP2939 is an investigational oral biologic consisting of EVs that it is developing for the potential treatment of inflammatory diseases. EDP1867 is a non-live pharmaceutical preparation of a single strain of Veillonella parvula, isolated from the ileum of a human donor.

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
EVELO BIOSCIENCES, INC.	-17.89%	759K
VERTEX PHARMACEUTICALS INCORPORATED	+5.33%	111B
REGENERON PHARMACEUTICALS, INC.	+12.11%	105B
BIONTECH SE	-12.56%	22.34B
ARGENX SE	-3.70%	21.93B
GENMAB A/S	-6.03%	18.59B
WUXI APPTEC CO., LTD.	-35.21%	18.12B
BEIGENE, LTD.	-10.86%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+5.10%	13.7B
SAREPTA THERAPEUTICS, INC.	+37.57%	12.45B

Bio Therapeutic Drugs